Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 24

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 24
---
 least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our ordinary shares that are held by non -affiliatesequals or exceeds $700 million as of the end of that year’s second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in non -convertibledebt securities during the prior three -yearperiod. References herein to “emerging growth company” will have the meaning associated with it in the JOBS Act. Additionally, we are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S -K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company for each fiscal year in which (1) the market value of our ordinary shares held by non -affiliatesis less than $250 million as of the end of the previous year’s second fiscal quarter, or (2) our annual revenues are less than $100 million during the previous completed fiscal year and the market value of our ordinary shares held by non -affiliatesis less than $700 million as of the end of the previous year’s second fiscal quarter. Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870 -3099. 10 DEFINITIONS Unless otherwise stated in this prospectus or the context otherwise requires, references to: •“amended and restated memorandum and articles of association”are to our Second Amended and Restated Memorandum and Articles of Association; •“Clear Street” are to Clear Street LLC; •“Companies Act” are to the Companies Act (As Revised) of the Cayman Islands, as may be amended from time to time; •“completion window” are the 15 -monthperiod following the completion of this offering (which may be extended without shareholder approval up to two times, each by an additional three months (for a total of up to 21 months to complete an initial business combination from the closing of this offering), subject to our sponsor depositing into the trust account $0.10 per public share outstanding in connection with each such extension) at the end of which, if we have not completed our initial business combination, we will redeem 100% of the issued and